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Supporting malaria elimination with
21st century antimalarial agent drug
discovery
Thierry T. Diagana
Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, Singapore 138670, Singapore
The burden of malaria has been considerably reduced over recent years. However, to achieve disease
elimination, drug discovery for the next generation needs to focus on blocking disease transmission and
on targeting the liver-stage forms of the parasite. Properties of the ‘ideal’ new antimalarial drug and the
key scientific and technological advances that have led to recent progress in antimalarial drug discovery
are reviewed. Using these advances, Novartis has built a robust pipeline of next-generation antimalarials.
The preclinical and clinical development of two candidate drugs: KAE609 and KAF156, provide a
framework for the path to breakthrough treatments that could be taking us a step closer to the vision
of malaria elimination.Introduction
Malaria is a devastating and often fatal disease caused by protozo-
an parasites from the Plasmodium genus. Owing to increased
prevention and control measures, such as the introduction of
insecticide-treated bed nets and use of artemisinin-based combi-
nation therapy, the burden of malaria has been reduced such that
between 2000 and 2013 global malaria mortality rates decreased by
47% [1]. Nevertheless, in 2013 an estimated 584 000 individuals
(90% from sub-Saharan Africa and 78% children <5 years of age)
died from malaria [1]. The current challenge is whether malaria
can be completely eliminated on a global scale. Several countries
have now developed and started to implement malaria elimina-
tion strategies [2], but it is widely accepted that currently available
drugs are not ideally suited for disease elimination campaigns [3].
Specifically, there is a need for safe single-dose therapies that are
also suitable for mass drug administration to asymptomatic car-
riers and capable of blocking malaria transmission through the
anopheles vector. In addition, chemoprophylaxis prevention
requires drugs that are able to eliminate the liver-stage forms of
the parasite (especially for Plasmodium vivax).
The looming threat of artemisinin drug resistance [4–6], cou-
pled with intense lobbying and the financial support of philan-
thropic organisations such as the Wellcome Trust and the Bill &E-mail address: thierry.diagana@novartis.com.
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private partnerships such as the Medicines for Malaria Venture
[7], triggered a recent surge in antimalarial drug discovery and
development activities [8,9]. These research efforts are focused on
identifying drugs with novel mechanisms of action. Ultimately,
this should mitigate the risk of cross-resistance with existing
antimalarials and, by targeting multiple stages of the malaria
parasite lifecycle, facilitate prevention, radical cure and transmis-
sion blocking [10].
Over the past 10 years, recognition of the need for antimalarial
agents with properties that differ from existing treatments has led
to dramatic changes in the way in which new targets are identified
and new drugs developed. Until very recently, no antimalarial
drug with a novel mechanism of action had entered Phase II
clinical trials since the hydroxy-1,4-naphthoquinone atovaquone
more than 20 years ago [11]. An important milestone in malaria
research, however, was achieved in early 2014 with the publication
of the results of a Phase II trial of KAE609 [12], the first member of a
novel class of antimalarials: the spiroindolones. KAE609 emerged
from a malaria drug discovery effort led by the Novartis Institute
for Tropical Diseases in partnership with the Genomics Institute of
the Novartis Research Foundation, the Swiss Tropical and Public
Health Institute, the Biomedical Primate Research Centre and the
Medicines for Malaria Venture, with financial support from the
Wellcome Trust. KAE609 is being further developed by Novartis as-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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elimination. This compound is the front-runner in a growing
pipeline of antimalarials emerging from Novartis that also
includes a second novel antimalarial, the imidazolopiperazine
KAF156 [13,14] currently in clinical trials [15], and a preclinical
programme aiming to develop inhibitors of phosphatidylinositol-
4-OH kinase [PI(4)K], a novel drug target that operates across all
the major lifecycle stages of the parasite in its host [16].
Here, we review and discuss the latest scientific and technologi-
cal advances in malaria drug discovery that have enabled the
development of a robust Novartis drug portfolio, and offer some
personal perspectives on the discovery and development of these
novel antimalarial agents. A comprehensive overview of the global
antimalarial pipeline has been the subject of another recent
publication [8].
Scientific and technological advances in antimalarial
drug discovery
Beyond already well-exploited drug targets, such as the Plasmodi-
um dihydrofolate reductase, dihydropteroate synthetase, cyto-
chrome bc1 complex and the haemoglobin degradation
pathway, there remains a dearth of novel validated targets. The
sequencing of the Plasmodium falciparum genome [17] and use of
modern genetics tools were expected to yield many attractive drug
targets, reviewed by Winzeler 2008 [18]. However, few proposed
targets have subsequently been chemically validated; most targets
validated by genetic knockouts have not been tractable. A notable
exception is the dihydroorotate dehydrogenase enzyme, which led
to the identification of the clinical candidate DSM265 [19];
DSM265 clinical studies represent the first attempt clinically to
validate a genetically identified target.
A number of scientific and technological advances have recently
enabled the rapid identification of clinical candidates and also
enabled the discovery and chemical validation of novel malaria
drug targets. Undoubtedly, the first important technological ad-
vance was the miniaturisation of Plasmodium growth assays
[20,21]. This development made automated HTS possible and
enabled Novartis and many other companies and academic groups
to screen large compound libraries for chemical ‘starting points’
with promising antimalarial activity [21–23]. An open-access re-
pository of screening data is available online at the ChEMBL –
Neglected Tropical Disease archive (https://www.ebi.ac.uk/
chemblntd) [24]. The second advance has been the development
of a wide array of genetic and biochemical techniques that have
enabled rapid identification of the molecular targets of different
screening hits [10,16,25–31].
An important barrier with respect to the elimination of malaria is
the liver stage of the parasite lifecycle, because P. vivax can remain
dormant in the liver as hypnozoites for many months or years [32].
Currently, the only treatment targeting the liver stage of vivax
malaria is primaquine, which cannot be used in individuals with
glucose-6-phosphate dehydrogenase deficiency, a common genetic
abnormality in malaria endemic areas. However, there is also a new
hypnozoiticidal compound in Phase III development: tafenoquine,
which might offer another liver-stage treatment in the future
[33,34]. The discovery of new liver-stage drugs has been hampered
by the dearth of models to screen for activity against hypnozoites;
until recently, only the in vivo Plasmodium-cynomolgi–simian malaria1266 www.drugdiscoverytoday.commodel was available. An important step towards the screening of
novel hypnozoiticidal compounds was recently made with estab-
lishment of an in vitro assay that discriminates the activity of
primaquine and atovaquone against the growing schizont and
dormant hypnozoite [35–37]. It was this assay that eventually
suggested the P. vivax radical cure potential of a novel class of
blood-stage antimalarial drugs: the imidazolopyrazines, which
target Plasmodium PI(4)K [16].
The availability of new drugs that prevent the transmission of
sexual-stage parasites (gametocytes) to mosquito vectors has also
been recognised as a crucial component of future malaria elimi-
nation strategies [38]. This task has been aided by the recent
development of a novel assay that utilises P. falciparum cell lines
to measure the effects of tested compounds on gametocyte matu-
ration and transmission [38]. A variety of in vitro assays have also
been employed to show that early- and late-stage gametocytes are
susceptible to KAE609 in a dose-dependent manner and that this
agent reduces transmission to the vector, providing further
evidence that blockage of transmission might be possible with
new-generation antimalarials [39].
Another important advance in malaria research was the devel-
opment and refinement of small animal models, reviewed by
Vaughan et al. [40] and Kaushansky et al. [41]. Humanised mouse
models, such as the severe combined immunodeficiency model,
enable the study of blood- and liver-stage P. falciparum and have
been used to establish the antimalarial potential of new drugs.
As a result of these advances, the emerging global pipeline for
new antimalarials [8,9] was identified using different discovery
strategies (e.g. target- vs cell-based hits). To have maximum public
health impact, novel antimalarial drugs must ideally fulfil a num-
ber of pharmacological and safety requirements throughout de-
velopment. We describe the various approaches employed by
Novartis and collaborators to ensure that drug candidates meet
these key pharmacological requirements.
Preclinical development strategy
In the preclinical profiling stages of drug development, the overall
goal is to ensure that the profile of a new drug candidate is
compatible with the probable use of the compound in the clinic.
To mitigate the risk of failure owing to a possible difference in
activity between laboratory-adapted strains and clinical isolates,
KAE609 was shown early to be as effective as artesunate in an ex
vivo assay against field isolates of P. falciparum and P. vivax collect-
ed from areas of drug resistance [42,43]. As noted, there are several
in vivo malaria models available for drug testing. The lethal Plas-
modium berghei malaria mouse is inexpensive, rapid and enables
the evaluation of cure (i.e. prevention of recrudescence) but
species differences in drug sensitivity might warrant the use of
the more expensive P. falciparum SCID model [19]. Potent antima-
larial activity across Plasmodium species is generally desirable
because it is suggestive of strong evolutionary conservation of
the compound-binding site on its molecular target, which is a
harbinger for a reduced risk of drug resistance development.
In preclinical species, KAE609 displayed pharmacokinetic pro-
files upon oral dosing consistent with once-daily oral dosing in
humans. In the P. berghei malaria mouse model, KAE609 demon-
strated a fast onset of action and potently reduced parasitaemia.
Importantly, KAE609 was the only one of the tested drugs (which
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display single-dose cure efficacy [42]. P. berghei appears in vitro to be
less sensitive to spiroindolones than P. falciparum and close ana-
logues of KAE609 display faster clearance antimalarial properties
in the P. falciparum SCID mouse (unpublished data).
The imidazolopiperazine class of compounds, which includes
KAF156, was also discovered and initially optimised primarily for
its asexual blood-stage activity, but was later found to show liver-
stage activity in vitro (Fig. 1) [44]. KAF156 displayed potent para-
sitaemia reduction at doses lower than those of standard antima-
larial drugs in blood-stage models, and also showed potent
prophylactic activity in the P. berghei mouse model. Thus, preclin-
ical data suggest that KAF156 could have clinical utility as a
therapeutic and prophylactic antimalarial agent [45]. Similar to
KAE609, the pharmacokinetic profile of KAF156 upon oral dosing
in preclinical species is compatible with once-daily dosing. In
terms of preclinical safety, oral doses of KAF156 were shown to
be well-tolerated in studies of rodents and dogs, with no toxicities
identified that would preclude use in humans.
New antimalarial drugs must also be fully tested in vitro with
regard to the potential for drug–drug interactions to minimise theGametocytes
ingested by
mosquito
Sporogony
Merozoit
R
Tropho
Erythrocytic
schizogony in
red blood cells
Schizont
Plasmodium vivax
hypnozoite
formation
Formation of
gametocytes
KAE609
KAF156∗
Gametocyte
Skin surface
FIGURE 1
Breaking the malaria life-cycle with novel antimalarials. * Potential for prophylactrisk of adverse interactions with other anti-infective therapies
frequently used in malaria-endemic countries, such as human
immunodeficiency virus and tuberculosis drugs. Many existing
antimalarial drugs carry some risk of cardiotoxicity through inhi-
bition of hERG-encoded potassium channels [46,47]. Given that
any novel antimalarial might be combined with some of these
drugs, it is important to minimise the risk for cardiotoxicity
through a thorough early evaluation of this risk in hERG in vitro
assays and animal toxicology studies. In addition, because the
populations most vulnerable to malaria are young children and
pregnant women, the drugs need to be tested as early as possible
with regard to their potential for reproductive toxicity, mutage-
nicity and genotoxicity. Because malaria is a tropical disease, it is
also important to assess the risk of phototoxicity in in vitro and in
vivo models [48]. KAF156 and KAE609 have been evaluated in these
safety pharmacology assays and no significant risks have been
identified [42,43,45]. Finally, the risk of drug resistance, together
with suitability for combination with existing agents to minimise
the risk of future resistance development, should also be assessed
at an early stage [49]. Drug resistance to KAE609 and KAF156 can
be generated in laboratory P. falciparum strains and, taking intoTransmission to
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the fold-shift drug resistance associated with single mutations, the
overall risk of resistance is viewed as moderate.
Clinical development strategy for new antimalarial
drugs
After Phase I healthy volunteer studies establish preliminary safety
and the maximum tolerated dose of a novel agent, demonstration
of the efficacy of a well-tolerated regimen predicted to deliver
therapeutic and efficacious drug levels is required in a small
proof-of-concept (PoC) Phase II study. This is usually performed
in patients with uncomplicated malarial infection and low-to-
moderate parasitaemia (<50 000 parasites/ml). Such PoC studies
also offer the opportunity to investigate the pharmacokinetics,
pharmacodynamics and tolerability of the drug in the target
population. Assuming the success of the PoC study, additional
Phase II studies might then be initiated to test whether single doses
of the drug are sufficient to cure acute infections and to define the
minimum inhibitory concentration (MIC) [50]. The final step
before large-scale Phase III trials can be initiated is usually dose-
range-finding studies evaluating various combination treatments
with other antimalarial drugs.
In a Phase I study (single and multiple ascending doses) in
healthy adult volunteers [51], KAE609 showed dose-proportional
pharmacokinetics (from 1 to 300 mg) with no significant food
effects. It has been proposed that for fast-acting antimalarial drugs
with a parasite reduction ratio of 104 cure can theoretically be
achieved in uncomplicated malaria patients if drug levels are
maintained above the MIC for three-to-four Plasmodium lifecycles
(144–192 h) [50]. In the KAE609 Phase I study, a single 200 mg
dose yielded drug levels above the in vitro IC99 for more than 144 h,
suggesting that a single-dose cure might be feasible. Although this
is an enthralling possibility, the in vitro IC99 might not accurately
predict the actual patient MIC and further patient trials are under-
way to determine whether single-dose cure can be achieved with
KAE609 (see below).
Subsequently, KAE609 underwent an open-label PoC trial in-
volving 21 patients with P. falciparum or P. vivax mono-infection
[12]. After treatment with 30 mg KAE609 daily for three days,
parasites were cleared in a median of 12 h, an effect that is more
rapid than that observed with artemisinin-based combination
therapies. In addition, in the five patients for whom gametocy-
taemia was detected at baseline (all with vivax malaria), gameto-
cytaemia was cleared by 8 h post-dose, confirming the potent
transmission-blocking potential of this novel class of compounds.
All patients recovered uneventfully, with no patients discontinu-
ing treatment as a result of adverse events. Absorption of KAE609
was reliable and the terminal elimination half-life (21 h) was
fully consistent with once-daily dosing. KAE609 is currently under
evaluation in another single-dose-range-finding Phase II trial that
will assess efficacy, safety and pharmacokinetics in uncomplicated
P. falciparum mono-infection and should provide information on
the feasibility of a 28-day single-dose cure [52]. Another Phase II
study will aim to identify the MIC of KAE609 in P. falciparum
mono-infection [53]. In terms of resistance, in vitro selection
resulted in strains with stable mutations, all mapping to the
PfATP4 gene [42]. It is therefore important that KAE609 is com-
bined with a second drug to protect it from the emergence of1268 www.drugdiscoverytoday.comresistance, particularly if the drug is ultimately used as a single-
dose therapy. Several preclinical and clinical studies are underway
or planned to evaluate potential drug partners to enable combi-
nation therapy in the clinic. A Phase IIb dose-ranging study and
concurrent safety studies with the selected drug partner would
follow, with a view to testing the optimal combination candidate
in Phase III non-inferiority studies versus the appropriate compar-
ator. The goal would then be to investigate the combination
treatment in children and pregnant patients further. Following
a strategy similar to KAE609, a Phase I study in healthy adults has
been completed for KAF156 [54] and a Phase II PoC study in
patients with uncomplicated P. vivax or P. falciparum infection
is underway [15]. Further studies could also be conducted utilising
a human sporozoite challenge model [55] to investigate the po-
tential prophylactic activity of KAF156.
Challenges and opportunities
Thanks to significant investments over the past decade and tech-
nological advances in HTS, the current global pipeline of new
antimalarial drug candidates is robust. Ironically, these successes
are now challenged by the fact that we might have identified most
– if not all – mechanisms accessible through HTS of conventional
compound libraries representing the currently accessible chemical
space [24]. Indeed, we suspect that most of our compounds active
against Plasmodium asexual stages act through a limited number of
known mechanisms and molecular targets [e.g. ATP4, PI(4)K,
dihydroorotate dehydrogenase, cytochrome bc1 complex and
dihydrofolate reductase]. Accessing alternative mechanisms of
action will probably require the use of different screening proce-
dures with different culture conditions and assay readouts.
Although most of the current clinical candidates have been
identified for their asexual blood-stage activity, many have addi-
tional activity against the sexual stages and the developing liver
stages, which could offer prevention and disease-transmission-
blocking properties. Unfortunately, activity against the hypno-
zoite remains extremely rare and further investments to develop
liver- and blood-stage culture systems for the P. vivax parasite are
desperately needed.
A number of challenges can also be identified with respect to the
clinical stages of drug development. Firstly, for new investigation-
al drugs, access to non-immune patients in a good clinical practice
(GCP)-compliant setting is restricted to few countries (mainly in
South-East Asia) and, therefore, our knowledge of the efficacy and
safety of new drugs in diverse populations is relatively limited.
Secondly, current methods of dose finding for new antimalarial
drugs are imprecise, such that some agents have been introduced
in the field at suboptimal doses. This potentially exacerbates
emergence of resistance and results in inefficient treatment of
the patient [50]. Recent recognition of the importance of identi-
fying the optimal dose has led to proposals for alternative dose-
finding strategies in specific patient populations, discussed by
White [50]. In this context, the recent and promising results
obtained in a malaria challenge model using healthy volunteers
could allow some of these limitations to be overcome [56,57].
A third key challenge for clinical development lies in the selec-
tion of the most appropriate partner drug for combination treat-
ment and in the strategies employed to study these combinations
once they are selected. Existing drugs, such as piperaquine or
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enable an accelerated development path towards registration,
whereas new chemical entities might require additional preclinical
and clinical safety studies. By contrast, combinations that consist
of entirely new chemical entities could enable an aggressive global
roll-out once the combination has been approved because there
are no concerns over pre-existing drug resistance. For each novel
drug combination the decision tree could vary slightly depending
on the constituent drug profiles because many pharmacological
factors can influence the optimal drug combination strategy. Of
utmost importance is ensuring all new antimalarial drugs are made
available to the most vulnerable populations as early as possible,
which necessitates rapid clinical evaluation in children and preg-
nant women for whom the tolerance to safety risk is lowest.
Concluding remarks
Over the past decade, significant progress has been made in the
global fight against malaria. More recently, a series of scientific and
technological advances have led to the development of a new
generation of antimalarial candidate drug that holds much prom-
ise. In particular, KAE609 and KAF156 might possess some of the
attributes of an ‘ideal’ antimalarial and, in combination with other
drugs, have the potential to become the first of a new generation of
malaria therapies to reach the clinic. Although large-scale trials are
still required and several research and clinical development issuesremain to be addressed, new drugs such as KAE609 and KAF156
will help to ensure there is sustained pressure on the parasite and,
thus, take us a step closer to eliminating this devastating disease.
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